ACT 2024 -- OCI-B2 is a potential therapy for COVID-19 through immune modulation allowing B cell stimulation to fight the virus by inhibiting cascades leading to acute respiratory distress syndrome (ARDS). The first-in-human nonclinical safety assessment package was undertaken using the inhaled route. Inhalation delivery directly to lungs is important due to compromised pulmonary circulation in ARDS. Minipig was identified as the most suitable non-rodent species due to metabolic profiling. Favorable toxicology results enabled progression to Phase I clinical trial.

• Download